Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive cancer with a focus on breast cancer

Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications

Volumn , Issue , 2013, Pages 179-210

  Rugo, Hope S ^a   Krop, Ian E ^b   Chu, Yu Waye ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84973351543     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5456-4_11     Document Type: Chapter

References (45)

1. Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-184
2. Dawood S, Broglio K, Buzdar AU et al (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92-98
3. Galsky MD, Von Hoff DD, Neubauer M et al (2012) Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs 30(2):695-701. doi:10.1007/s10637-010-9541-0
4. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
5. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
6. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:4247-4250
7. Trastuzumab (Herceptin(r)) Investigator Brochure, Genentech, Inc., South San Francisco, CA, July 2007
8. Lapatinib (Tykerb(r)) Product Insert, GlaxoSmithKline, 2008
9. Johnston S, Pippen J, Pvot X et al (2009) Lapatinib combined with Letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546
10. Spector NL, Xia W, Burris H 3rd et al (2005) Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 23:2502-2512
11. Krop I, Beeram M, Modi S et al (2010) A phase I study of trastuzumab-DM1, a HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2+ metastatic breast cancer. J Clin Oncol 28:2698-2704
12. Remillard S, Rebhun LI, Howie GS, Kupchan SM (1975) Antimitotic activity of the potent tumor inhibitor maytansine. Science 189:1002-1005
13. Cassady JM, Chan KK, Floss HG, Leistner E (2004) Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull 52:1-26
14. Widdison WC et al (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392-4408
15. Data-on-file, Genentech, Inc., South San Francisco, CA, July 2007
16. Lewis-Phillips GD, Li G, Dugger DL (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 6:9280-9290
17. Junttila T, Fields C, G. Li, et al (2008) Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is effective in combination with docetaxel. European Organization for Research and Treatment of Cancer Annual Meeting. Abstract #515, 2008
18. Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab Vedotin (SGN-35) for relapsed CD30-positive lymphomas. NEJM 363:1812-1821
19. Austin CD, De Maziere AM, Pisacane PI et al (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15:5268-5282
20. Austin CD, Wen X, Gazzard L et al (2005) Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. PNAS 102: 17987-17992
21. Shen B-Q, Bumbaca D, Saad O et al (2011) Metabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism [Poster PIII-72]. Clin Pharmacol Ther 89(Suppl 1):S90
22. Dieras V, Harbeck N, Albain K et al (2010) A phase Ib/II trial of trastuzumab-DM1 with per- tuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results [abstract P3-14-01]. Cancer Res 70(Suppl 2):291s
23. Krop IE, Modi S, Elias A et al (2010) A dose-escalation study of trastuzumab-DM1 (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive, locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen. Abstract P3-14-10. Cancer Res 70(Suppl 2):295s
24. Holden SN, Beeram M, Krop IE, et al (2008) A phase I study of weekly dosing of trastuzumab- DM1 in patients with advanced HER2+ breast cancer. J Clin Oncol 26(Suppl): abstract 1029
25. Burris HA, Rugo HS, Vukelja SA et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)- positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405
26. Krop I, LoRusso P, Miller KD, et al (2010) A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy [abstract 2770]. Presented at 35th ESMO Congress, 8-12 October 2010, Milan, Italy
27. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
28. Wolff AC, Hammond M, Schwartz J et al (2007) American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43
29. Press MF, Sauter G, Bernstein L et al (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598-6607
30. LoRusso P et al (2010) Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy, Abstract 1016. J Clin Oncol 28: 15s-118s
31. Tolcher AW, Ochoa L, Hammond LA et al (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 21:211-222
32. Ewer SM, Ewer MS (2008) Cardiotoxicity profile of trastuzumab. Drug Saf 31:459-467
33. Lu D, Gupta M, Wang B, et al (2011) An integrated population pharmacokinetic model for a first-in-class HER2 targeted antibody-drug conjugate trastuzumab emtansine (T-Dm1): simultaneous modeling of T-DM1 and total trastuzumab pharmacokinetics in heavily pretreated HER2-positive metastatic breast cancer patients. Presented at The American Society of Clinical Pharmacology and Therapeutics 2011 Annual Meeting
34. Gupta M, LoRusso PM, Wang B et al (2012) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab-DM1, a HER2- targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharm 52(5):691-703
35. Hurvitz SA, Dirix L, Kocsis J et al (2011) Trastuzumab emtansine (T-DM1) versus trastuzumab + docetaxel in previously untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976). ESMO Annual Meeting. Abstract 5001
36. Kirkova J, Davis MP, Walsh D et al (2006) Cancer symptom assessment instruments: a systematic review. J Clin Oncol 24:1459-1473
37. Baselga J et al (2010) First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. SABCS 2010. Abstract 291
38. Gianni L, et al (2010) Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (NeoSphere). SABCS 2010. Abstract S3-2.
39. Bang Y-J, Cutsem EV, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro- oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376:687-697
40. Nishiyama M, Eguchi H (2009) Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy. Adv Drug Deliv Rev 61:402-407
41. Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402
42. Scaltriti M, Rojo F, Ocana A et al (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. JNCI 99:628-638
43. Verma S et al (2012) Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med
44. Bender BC et al (2012) A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol
45. Baselga J et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109-119